Molecular structure of TCS PIM-1 4a, CAS Number: 438190-29-5
TCS PIM-1 4a (CAS 438190-29-5)
Alternate Names:
(5Z)-5-[[3-(Trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione thiazolidine-2,4-dione, 4a; SMI-4a
Application:
TCS PIM-1 4a is a selective and ATP-competitive Pim kinase inhibitor
CAS Number:
438190-29-5
Purity:
>98%
Molecular Weight:
273.23
Molecular Formula:
C11H6F3NO2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
TCS PIM-1 4a is a selective and ATP-competitive Pim kinase inhibitor (IC50 values = 24 and 100 nM for Pim-1 and Pim-2, respectively). TCS PIM-1 4a may act to display selectivity over a panel of approximately 50 other kinases tested. This compound also exhibits cytotoxicity in PC3 prostate carcinoma cells in vitro. TCS PIM-1 4a is an inhibitor of Aldose Reductase and Cox-2.
TCS PIM-1 4a (CAS 438190-29-5) References
- PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. | Fan, RF., et al. 2017. Mol Med Rep. 16: 4603-4612. PMID: 28849186
- Ginsenoside G-Rh2 synergizes with SMI-4a in anti-melanoma activity through autophagic cell death. | Lv, DL., et al. 2018. Chin Med. 13: 11. PMID: 29483938
- PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway. | Kuang, X., et al. 2019. Life Sci. 219: 248-256. PMID: 30658101
- Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. | Jiang, W., et al. 2019. Onco Targets Ther. 12: 3043-3050. PMID: 31114247
- PIM1 inhibitor SMI-4a attenuated lipopolysaccharide-induced acute lung injury through suppressing macrophage inflammatory responses via modulating p65 phosphorylation. | Wang, J., et al. 2019. Int Immunopharmacol. 73: 568-574. PMID: 31203114
- Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer. | Han, X., et al. 2019. Oncogene. 38: 6537-6549. PMID: 31358902
- Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells. | Zhang, X., et al. 2020. Mol Immunol. 125: 15-22. PMID: 32619930
- PIM1 inhibition attenuated endotoxin-induced acute lung injury through modulating ELK3/ICAM1 axis on pulmonary microvascular endothelial cells. | Cao, Y., et al. 2021. Inflamm Res. 70: 89-98. PMID: 33185705
- Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. | You, KS., et al. 2021. Cancers (Basel). 13: PMID: 33801977
- Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells. | Yi, YW., et al. 2022. Cancers (Basel). 14: PMID: 36358633
Inhibitor of:
Aldose Reductase, Cox-2, Pim-1, Pim-2, and Pim-3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCS PIM-1 4a, 10 mg | sc-296450 | 10 mg | $64.00 | |||
TCS PIM-1 4a, 50 mg | sc-296450A | 50 mg | $346.00 |